Why the study?
Current clinical surrogate markers and blood tests do not adequately predict individual risk of cardiovascular disease, necessitating more precise tools to predict individual thrombosis and bleeding risks.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
May inform multimodal Virchow's triad assessment; leaves open prospective validation before guiding individualized risk prediction.
Cardiovascular disease remains the leading cause of death in the era of modern medicine despite major advancements in this field. Current available clinical surrogate markers and blood tests do not adequately predict individual risk of cardiovascular disease. A more precise and sophisticated tool that can reliably predict the thrombosis and bleeding risks at an individual level is required in order for clinicians to confidently recommend early interventions with a favorable risk-benefit profile. Critical to the development of this tool is the assessment and understanding of Virchow's triad and its complex interactions between hypercoagulability, endothelial dysfunction and vessel flow, a fundamental concept to the development of thrombosis. This review explores the pathophysiology of cardiovascular disease stemming from the triad of factors and how individualized risk assessment can be improved through the multimodal use of tools such as global coagulation assays, endothelial biomarkers and vessel flow assessment.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: